The mortality rate of portal hypertension complicated with variceal bleeding in decompensated liver cirrhosis patients decreased dramatically in recent three decades,mainly benefited from the“forward blood flow”hypothesis proposed in the 1980s and splanchnic vascular tone theory to explain the mechanism of portal hypertension in advanced liver cirrhosis,thereby introducing clinically three types of drugs,namely,somatostatin and its derivatives,terlipressin,and nonselective beta blockers. The abovementioned drugs together with endoscopic variceal ligation, sclerotherapy and histoacryl injection have made a milestone contribution to the dramatic decreasing of mortality rate in liver cirrhosis patients with portal hypertension and bleeding. Recent advances in knowledge on the molecular mechanisms of increase of hepatic portal blood inflow,hepatic sinusoidal endothelium dysfunction and neovascularization form the basis of current emerging therapies for portal hypertension. We can expect that most likely this will result in more effective treatment and prevention for portal hypertension in liver cirrhosis patients.

Acromegaly is an endocrine and metabolic disease with insidious onset. Delays in its diagnosis and treatment significantly increase the incidence of complications. Early detection, diagnosis, and treatment are extremely important for the prognosis of patients with acromegaly. Based on a large quantity of evidence in recent years, Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020) has standardized the diagnosis and the treatment strategies of acromegaly. In the non-surgical treatment section, according to the categories of drugs used to treat acromegaly, the indications, selection, administration, dosage and precautions of pharmaceutical treatment have been clarified with specific recommendations. It is hoped that the new consensus can further guide and standardize the clinical management of acromegaly.

Allergens ; analysis ; Animals ; Cattle ; Child ; Humans ; Immunoglobulin E ; analysis ; Infant ; Milk Hypersensitivity ; diagnosis ; therapy ; Practice Guidelines as Topic ; Skin Tests

Humans ; Infant ; Rickets ; diagnosis ; pathology ; Risk Factors ; Vitamin D Deficiency ; complications ; diagnosis ; pathology

Adult ; Arsenic Poisoning ; Arsenicals ; Humans ; Indium ; Male ; Occupational Exposure ; Young Adult

Eating ; physiology ; psychology ; Feeding Behavior ; psychology ; Humans ; Infant ; Sense Organs ; physiology

Animals ; China ; epidemiology ; Clinical Trials as Topic ; Evidence-Based Medicine ; Humans ; Infant ; Infant, Newborn ; Milk Hypersensitivity ; diagnosis ; epidemiology ; therapy ; Milk Proteins ; adverse effects ; immunology ; Practice Guidelines as Topic ; standards ; Skin Tests ; methods

Guidelines as Topic ; Humans ; Infant ; Infant, Newborn ; Nutritional Physiological Phenomena

e scale clinical trials.

Carbohydrate antigen-125 is a nonspecific tumor marker,which was used as an aid in the diagnosis and monitoring of patients with ovarian cancer in the past.But recent studies find that CA-125 in patients with liver disease also has different expression levels.In this article,we review the expression levels,related mechanisms and the significance of CA-125 in different liver disease.